Member Login
Customer Login
(CercleFinance.com) – Valneva announces that the European Commission has granted marketing authorization (MA) to Ixchiq, its single-dose vaccine for the prevention of disease caused by the chikungunya virus in people aged 18 years and older.
The authorization of the vaccine was unanimously approved by Member States following a rigorous assessment carried out by the European Medicines Agency (EMA), based on data from a pivotal phase 3 study and published in The Lancet.
Valneva thus receives a third Marketing Authorization for Ixchiq after approvals from the American FDA and Health Canada. The company plans to deliver the first doses of the vaccine to Europe in the fourth quarter of 2024.
Associated values
| 3,36 EUR | Euronext Paris | +5,59% |
Copyright (c) 2024 Cercle Finance. The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. Cercle Finance cannot be held responsible directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional advisor before making any investment. This indicative information does not in any way constitute an inducement to sell or a solicitation to buy.
